If the Secretary designates a drug under section 355f(d) of this title as a qualified infectious disease product, then the Secretary shall
give priority review to the first application submitted for approval for such drug
under section 355(b) of this title, or section 262(a) of Title 42, that requires clinical data (other than bioavailability studies) to demonstrate
safety or effectiveness.
Nothing in this section shall prohibit the Secretary from giving priority review to
a human drug application or efficacy supplement submitted for approval under section 355(b) of this title that otherwise meets the criteria for the Secretary to grant priority
FindLaw Codes may not reflect the most recent version of the law in your jurisdiction. Please verify the status of the code you are researching with the state legislature or via Westlaw before relying on it for your legal needs.
Was this helpful?
Welcome to FindLaw's Cases & Codes
A free source of state and federal court opinions, state laws, and the United States Code. For more information about the legal concepts addressed by these cases and statutes, visit FindLaw's Learn About the Law.